Multiple Myeloma Life Expectancy: What Determines Long-Term Survival? Learn what determines multiple myeloma life expectancy, including stage, genetics, specialists, modern treatments, and evidence-based lifestyle strategies that may improve long-term survival.
Life expectancy for multiple myeloma ranges from less than two years to well over twenty years.
It depends on:
- Stage
- Cytogenetics
- Kidney function
- Age
- Overall health
- Response to treatment
- Whether you are treated by a myeloma specialist
- Access to newer therapies
- Management of treatment side effects
- Long-term lifestyle choices
Current data suggest:
- Overall 5-year relative survival is approximately 61%
- Survival continues improving because of:
- daratumumab
- CAR-T therapy
- bispecific antibodies
- maintenance therapy
- MRD-guided treatment decisions
Population statistics continue to improve every year. According to the American Cancer Society, the current five-year relative survival is approximately 61%, although individual prognosis varies tremendously depending on disease biology, treatment response, age, overall health, and access to myeloma specialists.
Newly diagnosed myeloma patients have a lot to look forward to. While oncology is currently working out the kinks in the therapies below, they hold a lot of future promise.
- CAR-T
- Bispecific antibodies
- MRD testing
- Quadruplet induction
- Personalized therapy
What determines life expectancy?
| Factor |
Effect on Survival |
| Myeloma specialist |
One of the strongest predictors |
| High-risk genetics |
Shorter survival |
| Standard-risk disease |
Better survival |
| MRD negativity |
Longer remissions |
| Kidney function |
Major prognostic factor |
| Bone disease |
influences quality of life |
| Fitness |
Determines treatment options |
| Lifestyle |
May influence long-term outcomes |
Life Expectancy Isn’t the Only Goal
Try to balance the quantity of life with the quality of life through:
- maintaining independence
- preserving cognition
- reducing neuropathy
- reducing fatigue
- minimizing cardiovascular disease
- maintaining bone health
- emotional health
Questions to Ask Your Myeloma Specialist
- What is my ISS, R-ISS or R2-ISS stage?
- Do I have high-risk cytogenetic abnormalities?
- How does my kidney function affect my prognosis?
- What depth of response should we aim for?
- Will MRD testing be useful in my case?
- How might transplant or maintenance therapy affect my outlook?
- What treatment options would remain if I relapse?
- Are there clinical trials appropriate for my risk group?
For all the talk of improved overall survival of MMers, I can’t look at these statistics and not wonder why newly diagnosed myeloma patients would focus solely on conventional therapy for their treatment without learning more about long-term MM survival.
My apologies- let me first explain how you, the newly diagnosed MM patient, can make a substantial jump in your life expectancy.
When I was diagnosed in 1994, median survival was measured in just a few years. Today, many patients live for a decade or more, and some live twenty years or longer. My own experience has convinced me that long-term survival depends on more than choosing the right chemotherapy—it also requires managing treatment toxicity, maintaining physical function, and making evidence-based lifestyle choices throughout survivorship.”
Work with, or at least consult with an oncologist who specializes in multiple myeloma. According to careful research, myeloma specialists provide much longer life expectancy statistics than general hematologists-oncologists.
This is not a slight to whomever you are currently working with (if he/she is not an MM specialist). MM is a rare cancer incorporating less than 2% of all cancer diagnoses in the United States annually. Further, there are over 100 different types of cancer.
Like any profession, if you work with, treat, study, etc., the same thing day in, day out, you will get better at it.
Right behind overall survival, aka life expectancy, I have to wonder about quality of life, aka how the newly diagnosed MMer feels day in and day out. In other words, if a newly diagnosed MMer can beat the odds by living longer than five years, he or she will experience a host of short-term, long-term, and late-stage side effects such as joint pain, chemobrain, peripheral neuropathy, bone pain, and more.
How does a newly diagnosed MMer enjoy a longer life expectancy as well as enjoy a reasonable quality of life while doing so? How does a newly diagnosed MM patient reach long-term survival?
Living with MM since early 1994 has taught me that
- You have a lot to learn- MM is a complicated, often aggressive cancer
- Oncology can be complex. MM patients need to know what to ask their oncology team and how to manage them from day one.
- Lastly, MM management is not conventional or non-conventional. It is not natural or toxic. It is not one or the other. MM patients must take the best of both traditional and non-traditional worlds in order to manage their MM for decades, not just years.
In short, combine conventional (FDA approved) with evidence-based non-conventional.
Have you been diagnosed with MM? What are your symptoms? What therapies are you considering? Scroll down the page, post a question or comment and I will reply to you ASAP.
Thank you,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
About the author: David Emerson is a long-term multiple myeloma survivor and director of PeopleBeatingCancer, a nonprofit cancer education resource. His writing combines survivor experience with research on conventional, complementary, and supportive cancer care.
How I Evaluate Therapies That May Affect Myeloma Outcomes
| Evidence rating |
Meaning |
| Strong |
Supported by guidelines, randomized trials, meta-analyses or consistent clinical evidence |
| Moderate |
Supported by smaller clinical trials or consistent observational research |
| Preliminary |
Early human evidence exists, but findings are limited or inconsistent |
| Laboratory only |
Evidence comes primarily from cell or animal studies |
| Insufficient |
Reliable evidence is not currently available |
| Potential interaction or harm |
May interfere with treatment or create safety concerns |
Suggested application
| Strategy |
Evidence level |
Interpretation |
| Evidence-based myeloma therapy |
Strong |
Primary method of controlling active multiple myeloma |
| Maintenance therapy for appropriate patients |
Strong |
Can prolong disease control, although benefits and risks vary |
| Exercise and rehabilitation |
Moderate |
Supports function, fatigue management and general health; not a stand-alone anticancer treatment |
| Balanced nutrition |
Moderate for supportive health |
Helps maintain strength and treatment tolerance; survival effects are not established |
| Individual supplements |
Varies |
Must be rated separately according to the evidence and interaction risk |
| Cell-study compounds |
Laboratory only |
Should not be described as proven to prolong life |
To learn more:
Frequently Asked Questions:
How long can a person live with multiple myeloma?
Some people live only several years, while others live 10, 15 or 20 years or longer. Prognosis depends on disease biology, age, health, response to treatment and the therapies available over time.
Can you live 20 years with multiple myeloma?
Yes. Long-term survival is possible, although it is not possible to predict at diagnosis who will live 20 years. Published averages include patients with widely different risk profiles and treatments.
Is multiple myeloma always terminal?
Multiple myeloma is usually considered treatable but not curable. It can become life-threatening, but many patients experience repeated periods of disease control and live for years after diagnosis.
What is the five-year survival rate for multiple myeloma?
Recent U.S. population data place five-year relative survival at approximately 60%–62%. These statistics reflect people diagnosed in earlier years and may not fully represent the results of the newest therapies.
Does Stage 3 multiple myeloma mean death is near?
No. Stage 3 indicates a higher-risk or greater-burden disease, but it does not predict an individual expiration date. Treatment response, genetics, organ function and access to newer therapies also matter.
Does remission improve life expectancy?
A deep, durable response is generally associated with better outcomes. However, the meaning of remission varies, and myeloma can eventually relapse even after an excellent response.
Can lifestyle changes cure multiple myeloma?
No lifestyle program has been proven to cure active multiple myeloma. Diet, exercise, sleep and supportive care may help preserve health and treatment tolerance but should complement—not replace—evidence-based oncology care.
Recommended Reading:
Research links
“I updated this post more than two years ago, and it has been very helpful to many in the myeloma patient community One thing has become very clear to me, the pace of change and progress for myeloma has become exponential. This is a very good thing! We have had 4 drugs approved for myeloma since 2015 (two are new classes of drugs)…”
“The survival of multiple myeloma patients has improved very significantly over the last decade. Still, median overall survival is inferior to 5 years. A small proportion of patients survive longer than 10 years. In this paper, we discuss four cases illustrating the nonhomogeneous clinical presentation and evolution of this subset of patients. Surprisingly, these long survivors do not always have deep responses and some require frequent treatments, which include autologous stem cell transplantation and novel drugs…
Toxicities associated with different treatments impact in the quality of life. Neurological, hematopoietic, and cardiac side effects are the most common toxicities in patients under prolonged treatment. They are associated with the broad use of alkylating agents, corticosteroids and, more recently, proteasome inhibitors and immunomodulators.
Also, survivors of MM are confronted with nonspecific, cancer treatment-related long-term symptoms, most commonly fatigue, sexual dysfunction, arthralgia, and a high risk of second primary malignancies (SPM) 18. High-dose chemotherapy with autologous stem cell support became widely used since 1990s in fit patients under 65 years of age…
With the aim of examining some factors that influence long-term survivorship, we present and discuss four different clinical cases of long-term survivors with MM, including both transplanted and nontransplanted patients with a variety of comorbidities and different treatments flow. These four patients diagnosed with MM for more than 10 years (13, 18, 19, and 20 years) were selected from the authors’ outpatient practice because they were alive and are representative of the true story and heterogeneity of MM worldwide…
Multiple Myeloma Life Expectancy
